Department of Surgery, University of Cincinnati College of Medicine, 6005 Given Road Cincinnati, OH 45243, USA.
Medical Writing, World Surgical Infection Society, Cincinnati, OH 45243, USA.
Future Microbiol. 2019 Oct;14:1293-1308. doi: 10.2217/fmb-2019-0135. Epub 2019 Oct 1.
Recently approved for use in complicated intra-abdominal infection, eravacycline is a novel fluorocycline with broad spectrum of activity against resistant Gram-negative pathogens. This manuscript is a pooled analysis of two Phase III trials. Clinical cure rates were 86.8% for eravacycline versus 87.6% for ertapenem, and 90.8% for eravacycline versus 91.2% for meropenem in the Intent to Treat (micro-ITT) populations, and 87.0% for eravacycline versus 88.8% ertapenem, and 92.4 versus 91.6% for meropenem in the Modified Intent to Treat (MITT) populations. Eravacycline is well tolerated, with lower rates of nausea, vomiting and diarrhea than other tetracyclines. Eravacycline is an effective new option for use in complicated intra-abdominal infections, and in particular, for the treatment of extended-spectrum β-lactamase- and carbapenem-resistant Enterobacteriaceae-expressing organisms.
最近批准用于复杂的腹腔内感染，依拉环素是一种新型氟环素，对耐药革兰氏阴性病原体具有广泛的活性。本文是两项 III 期试验的汇总分析。在意向治疗（微观 ITT）人群中，依拉环素的临床治愈率为 86.8%，而厄他培南为 87.6%，美罗培南为 90.8%；在改良意向治疗（MITT）人群中，依拉环素的临床治愈率为 87.0%，厄他培南为 88.8%，美罗培南为 92.4%。依拉环素耐受性良好，恶心、呕吐和腹泻的发生率低于其他四环素类药物。依拉环素是治疗复杂腹腔内感染的一种有效新选择，特别是用于治疗产超广谱β-内酰胺酶和碳青霉烯类耐药肠杆菌科表达的生物体。
